Adjuvant chemotherapy ups survival in mucinous colon cancer

  • Fields AC & al.
  • J Surg Oncol
  • 19 Sep 2019

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adjuvant chemotherapy is associated with better survival in stage II/III mucinous colon adenocarcinoma.

Why this matters

  • The prognosis and effect of adjuvant chemotherapy has not been clearly established in mucinous colon cancer, and this study is one of the largest to date.

Study design

  • Retrospective analysis of records from the National Cancer Database (n=31,041) with stage II/III mucinous colon adenocarcinoma.
  • Propensity-matched analysis: 3302 with stage II, 5564 with stage III.
  • Funding: None disclosed.

Key results

  • In adjusted analysis, there was no significant difference in survival between patients with stage II nonmucinous vs mucinous adenocarcinoma (HR, 0.99; P=.60).
  • Survival in stage III disease favored nonmucinous disease (HR, 1.05; P<.001>
  • Adjuvant chemotherapy was associated with better survival in mucinous adenocarcinoma:
    • Stage II: 5 years: 78.4% vs 73.7%; 10 years: 61.9% vs 54.3% (HR, 0.79; P.
    • Stage III: 5 years: 55.8% vs 36.8%; 10 years: 33.7% vs 19.2% (HR, 0.56; P

Limitations

  • Retrospective.
  • Limited information on specific chemotherapy regimens, adverse events.